

Ingvar Bjarnason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5038740/publications.pdf>

Version: 2024-02-01

41
papers

4,283
citations

331259

21
h-index

288905

40
g-index

44
all docs

44
docs citations

44
times ranked

4096
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-Reported Medication Adherence Among Patients with Ulcerative Colitis in Japan and the United Kingdom: A Secondary Analysis for Cross-Cultural Comparison. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 671-678.	0.8	1
2	NSAID-enteropathy and intestinal microbes. <i>Inflammopharmacology</i> , 2021, 29, 1-4.	1.9	9
3	Role of Helicobacters in Neuropsychiatric Disease: A Systematic Review in Idiopathic Parkinsonism. <i>Journal of Clinical Medicine</i> , 2020, 9, 2159.	1.0	7
4	A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis. <i>International Journal of Pharmaceutics</i> , 2020, 587, 119648.	2.6	51
5	Distinctive Pathophysiology Underlying Constipation in Parkinson's Disease: Implications for Cognitive Inefficiency. <i>Journal of Clinical Medicine</i> , 2020, 9, 1916.	1.0	6
6	Validation of the English version of the difficulty of life scale for patients with ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 312-317.	0.8	4
7	Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. <i>Current Gastroenterology Reports</i> , 2019, 21, 55.	1.1	32
8	<i>Helicobacter suis</i> Is Associated With Mortality in Parkinson's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 188.	1.2	14
9	A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. <i>Inflammopharmacology</i> , 2019, 27, 465-473.	1.9	110
10	Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. <i>Gastroenterology</i> , 2018, 154, 500-514.	0.6	310
11	Differing disintegration and dissolution rates, pharmacokinetic profiles and gastrointestinal tolerability of over the counter ibuprofen formulations. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 223-233.	1.2	5
12	A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. <i>Inflammopharmacology</i> , 2017, 25, 499-509.	1.9	26
13	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. <i>Gastroenterology</i> , 2017, 152, 980-982.e3.	0.6	57
14	Reply. <i>Gastroenterology</i> , 2017, 153, 612-613.	0.6	1
15	The Use of Fecal Calprotectin in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 53-56.	0.2	32
16	Early change in faecal calprotectin predicts primary non-response to anti-TNF therapy in Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1447-1452.	0.6	19
17	Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 441-450.	1.1	9
18	A new form of chronic inflammatory bowel disease associated with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 644-645.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. <i>Journal of NeuroVirology</i> , 2016, 22, 22-32.	1.0	42
20	KRAS Mutant Status, p16 and β -catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer. <i>Anticancer Research</i> , 2016, 36, 5315-5324.	0.5	2
21	Antitumor necrosis factor treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 1455-1456.	1.3	9
22	Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis. <i>EBioMedicine</i> , 2015, 2, 1523-1527.	2.7	20
23	Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 255-263.	0.6	55
24	Aspirin Induced Adverse Effects on the Small and Large Intestine. <i>Current Pharmaceutical Design</i> , 2015, 21, 5089-5093.	0.9	23
25	BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia. <i>Anticancer Research</i> , 2015, 35, 2345-50.	0.5	12
26	Feasibility of small bowel capsule endoscopy in children under the age of 4 years: a single centre experience. <i>Frontline Gastroenterology</i> , 2012, 3, 267-271.	0.9	4
27	NSAIDs: take with food or after fasting?. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 465-469.	1.2	41
28	Commentary: We came to an overwhelming and uniform opinion that these reports do not show colitis. <i>BMJ: British Medical Journal</i> , 2011, 343, d6979-d6979.	2.4	2
29	Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. <i>Journal of Gastroenterology</i> , 2009, 44, 23-29.	2.3	130
30	Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1156-1163.	2.4	36
31	Probiotic prophylaxis in predicted severe acute pancreatitis. <i>Lancet, The</i> , 2008, 372, 114-115.	6.3	10
32	Long-Term Effects of Nonsteroidal Anti-Inflammatory Drugs and Cyclooxygenase-2 Selective Agents on the Small Bowel: A Cross-Sectional Capsule Enteroscopy Study. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1040-1045.	2.4	249
33	Role of bile in pathogenesis of indomethacin-induced enteropathy. <i>Archives of Toxicology</i> , 2007, 81, 291-298.	1.9	42
34	Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. <i>Journal of the Royal Society of Medicine</i> , 2007, 100 Suppl 48, 11-4.	1.1	2
35	Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug-Induced Clinical Relapse in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 196-202.	2.4	261
36	A Quantitative Analysis of NSAID-Induced Small Bowel Pathology by Capsule Enteroscopy. <i>Gastroenterology</i> , 2005, 128, 1172-1178.	0.6	450

#	ARTICLE	IF	CITATIONS
37	COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. <i>Gastroenterology</i> , 2002, 122, 1913-1923.	0.6	182
38	Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2000, 119, 15-22.	0.6	708
39	Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. <i>Arthritis and Rheumatism</i> , 1996, 39, 1998-2003.	6.7	157
40	Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. <i>Gastroenterology</i> , 1993, 104, 1832-1847.	0.6	957
41	BLOOD AND PROTEIN LOSS VIA SMALL-INTESTINAL INFLAMMATION INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. <i>Lancet, The</i> , 1987, 330, 711-714.	6.3	194